CWC
NTLA icon

Carolinas Wealth Consulting’s Intellia Therapeutics NTLA Stock Holding History

Carolinas Wealth Consulting’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,000
Closed -$21K – 984
2020
Q2 		$21K Buy
+1,000
New +$17K 0.01% 284

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Carolinas Wealth Consulting's NTLA Position: Q3 2020 in Review

Carolinas Wealth Consulting sold out of Intellia Therapeutics (NTLA) in Q3 2020, closing a stake of 1,000 shares — an estimated $21K sold.

Carolinas Wealth Consulting first reported a position in NTLA in Q2 2020 and held it in 1 quarter. The position peaked at $21K in Q2 2020. 165 funds tracked by Wall St. Rank hold NTLA as of Q3 2020.

  • Carolinas Wealth Consulting reported no remaining Intellia Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 1,000 Intellia Therapeutics shares in Q3 2020, an estimated $21K.
  • Carolinas Wealth Consulting first reported a position in Intellia Therapeutics in Q2 2020 and held it in 1 quarter.
  • Carolinas Wealth Consulting's Intellia Therapeutics position peaked at $21K in Q2 2020.
  • 165 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2020.

Based on Carolinas Wealth Consulting's 13F filing for Q3 2020, filed 12 Nov 2020.